Lenalidomide
Small molecule
Also known as CC-5013, CDC-501
Evidence outlook
Approved: Multiple Myeloma, Follicular Lymphoma, Myelodysplastic Syndromes, Mantle Cell Lymphoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (3)
- Marginal Zone Lymphoma REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).
- Treatment of relapsed or refractory multiple myeloma
- Multiple myeloma Revlimid as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Revlimid as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00056160 NCT00056160 · Multiple Myeloma This randomized, quadruple-blind, placebo-controlled Phase 3 trial enrolled 353 patients with previously treated multiple myeloma and used a hard clinical primary endpoint, time to tumor progression. The primary comparison was met: median TTP was 60.1 weeks (95% CI 41.1–80.0) with lenalidomide plus dexamethasone versus 20.1 weeks (95% CI 16.1–21.1) with placebo plus dexamethasone, a large, clearly favorable separation. The trial's strong design and positive primary result make this high-quality evidence for lenalidomide. Registry: NCT00056160 | 3 | Time to Tumor Progression (TTP) (60 weeks (median Time To Progression of CC-5013/Dex treatment group)) 2005-11-01 | Time to Tumor Progression (TTP) (60 weeks (median Time To Progression of CC-5013/Dex treatment group)): CC-5013/Dex 60.1 Weeks (95% CI 41.1 to 80) vs Placebo/Dex 20.1 Weeks (95% CI 16.1 to 21.1) | Reliable signal | link ↗ |
View 1 more trial
NCT00424047 NCT00424047 · Multiple Myeloma This was a randomized, quadruple-blind, placebo-controlled trial involving 351 participants. Its primary clinical endpoint, time to tumor progression, was significantly improved with lenalidomide plus dexamethasone compared with dexamethasone plus placebo (hazard ratio 0.324, p<0.001). Registry: NCT00424047 | 3 | Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months); Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (Later Cut-off Date of 02 Mar 2008) (From randomization up to cut-off date of 02 March 2008; up to 51 months) 2005-11-01 | Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months): Lenalidomide Plus Dexamethasone 52.1 weeks vs Placebo Plus Dexamethasone 20.1 weeks (95% CI 16.6 to 20.7) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (137)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (504)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (175)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (203)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (18)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (22)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (28)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (17)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (3)
What this study did
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Phase 4 (1)
What this study did
Appears in other studies (14)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Cereblon E3 ubiquitin-ligase drugs
Iberdomide, Thalidomide, Mezigdomide, Cemsidomide, ICP-490 and 1 more. Compare all 7 Cereblon E3 ubiquitin-ligase drugs
6 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Follicular Lymphoma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Lenalidomide: this drug | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Thalidomide Analog | not yet graded | No reviewed efficacy summary in this indication | |
| Epcoritamab | Approved | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Interferon Alfa-2b (Intron A) | Approved | Biologic (subtype unspecified) | Type I interferon receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Obinutuzumab | Approved | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | Reliable signal | NCT02213263: Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 (Week 26): Rituximab-EU 70.7 percentage of participants (95% CI 63.8 to 76.9) | PF-05280586 75.5 percentage of participants (95% CI 68.9 to 81.4) | |
| Rituximab (Rituxan) | Approved | Monoclonal antibody | CD20, CD20-directed Cytolytic Antibody | not yet graded | No reviewed efficacy summary in this indication | |
| Tafasitamab | Approved | Monoclonal antibody | CD19 | Reliable signal | No reviewed efficacy summary in this indication | |
| Zanubrutinib (Brukinsa) | Approved | Small molecule | BTK | not yet graded | No reviewed efficacy summary in this indication | |
| Obinutuzumab Beta (Bejescin) | Phase 3 | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Odronextamab | Phase 3 | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Surovatamig | Phase 3 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Zugocabtagene Geleucel | Phase 1/2 | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(196 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Lenalidomide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.